A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective against Triple Negative Breast Cancer via Multiple Mechanisms of Action

A Novel Bispecific Antibody Targeting EGFR and VEGFR2 Is Effective against Triple Negative Breast Cancer via Multiple Mechanisms of Action

Both EGFR and VEGFR2 frequently overexpress in TNBC and cooperate with each other in autocrine and paracrine manner to enhance tumor growth and angiogenesis. Therapeutic mAbs targeting EGFR (cetuximab) and VEGFR2 (ramucirumab) are approved by FDA for numerous cancer indications, but none of them are...

Full description

Bibliographic Details
Main Authors: Nishant Mohan, Xiao Luo, Yi Shen, Zachary Olson, Atul Agrawal, Yukinori Endo, David S. Rotstein, Lorraine C. Pelosof, Wen Jin Wu
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
EGFR
VEGFR2
bispecific antibody (BsAb)
triple-negative breast cancer (TNBC)
autocrine and paracrine
Online Access:https://www.mdpi.com/2072-6694/13/5/1027

Internet

https://www.mdpi.com/2072-6694/13/5/1027

Similar Items